FASL antibody

Catalog No. ABIN1105941

Product Details anti-FASL Antibody

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Reactivity: Human

Host: Hamster

Clonality: Monoclonal

Conjugate: This FASL antibody is un-conjugated

Application: Enzyme Immunoassay (EIA)

Specificity: This antibody reacts with Fas Ligand.

Cross-Reactivity (Details): Species reactivity (tested):Human

Purification: Protein A agarose

Immunogen: Recombinant human Fas Ligand

Clone: 4H9

Isotype: IgG

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: PBS containing 50 % glycerol, pH 7.2. Contains no preservatives.

Preservative: Without preservative

Handling Advice: Avoid repeated freezing and thawing.

Storage: -20 °C

Storage Comment: Store (in aliquots) at -20 °C.

Target Details for FASL

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Alternative Name: CD178 / Fas Ligand (FASL Products)

Synonyms: ALPS1B antibody, APT1LG1 antibody, APTL antibody, CD178 antibody, CD95-L antibody, CD95L antibody, FASL antibody, TNFSF6 antibody, fasl antibody, Fas-L antibody, Faslg antibody, Tnfsf6 antibody, gld antibody, Apt1Lg1 antibody, Fasl antibody, FASLG antibody, zgc:162027 antibody, Fas ligand antibody, Fas ligand L homeolog antibody, Fas ligand (TNF superfamily, member 6) antibody, FASLG antibody, faslg.L antibody, Fasl antibody, Faslg antibody, faslg antibody

Background: Fas ligand (FasL/CD178/CD95L) is a type II-membrane protein, belonging the tumor necrosis factor (TNF)/nerve growth factor (NGF) family. It is known that engagement of Fas (receptor of FasL) by FasL causes apoptotic cell death. FasL is predominantly expressed in activated T lymphocytes and Natural Killer (NK) cells and expressed in the tissues of the immune-privilege sites such as the testis and eye. On the other hand, Fas is expressed in various tissues with abundant expression in the thymus, liver, heart, and kidney. Furthermore, a variety of cancers such as melanomas were found to express FasL in addition to Fas. It is said that the Fas/FasL system is involved in the deletion of dangerous activated or autoreactive T and B cells, and in turn plays a role in human diseases such as fulminant hepatitis, AIDS, cancers and other diseases involving CTL-induced tissue destruction. Furthermore, FasL can be used as an immune-suppressive agent. Rejection of transplants is mediated by activated T cells that may express functional Fas. If a transplanted tissue is engineered to express FasL or is co-transplanted with FasL-expressing cells, the transplant may be tolerated.Synonyms: APT1LG1, APTL, Apoptosis antigen ligand, CD95L protein, FASL, FASLG, Fas antigen ligand, TNFSF6, Tumor necrosis factor ligand superfamily member 6

Gene ID: 356

NCBI Accession: NP_000630

UniProt: P48023

Pathways: Apoptosis, EGFR Signaling Pathway, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity